AMMAR TRABOULSI: Open Payments
NPI 1225125610 · NEW LONDON, CT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$660 in 31 payments from 10 companies in 2025. Trend: 2023 $513 · 2024 $420 · 2025 $660
Food & beverage: $660
| Company | Payments | Amount |
|---|---|---|
| Supernus Pharmaceuticals, Inc. | 16 | $217 |
| Janssen Pharmaceuticals, Inc | 1 | $125 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $99 |
| Otsuka America Pharmaceutical, Inc. | 3 | $58 |
| Alkermes, Inc. | 2 | $55 |
| Neurocrine BioSciences, Inc. | 1 | $27 |
| ABBVIE INC. | 1 | $22 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
| Lundbeck LLC | 1 | $20 |
| E.R. Squibb & Sons, L.L.C. | 1 | $18 |
Products named: Qelbree, SPRAVATO, CAPLYTA, REXULTI, ARISTADA, INGREZZA, VRAYLAR, TRINTELLIX.
Industry payments across CT — which companies pay providers there.
